Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of “Buy” by Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have earned a consensus rating of “Buy” from the eleven research firms that are covering the stock, MarketBeat reports. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $58.20.

A number of equities analysts recently issued reports on MIRM shares. HC Wainwright raised their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Robert W. Baird raised their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research note on Thursday, February 27th.

Mirum Pharmaceuticals Price Performance

Shares of MIRM stock opened at $45.99 on Tuesday. Mirum Pharmaceuticals has a fifty-two week low of $23.14 and a fifty-two week high of $54.23. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of -22.77 and a beta of 1.04. The stock’s 50-day simple moving average is $48.01 and its 200-day simple moving average is $43.87.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The company had revenue of $99.41 million for the quarter, compared to analysts’ expectations of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. As a group, equities analysts forecast that Mirum Pharmaceuticals will post -1.43 earnings per share for the current fiscal year.

Insider Activity at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 1,998 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $85,554.36. Following the sale, the chief operating officer now directly owns 27,015 shares of the company’s stock, valued at $1,156,782.30. This represents a 6.89 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Christopher Peetz sold 7,489 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $320,678.98. Following the sale, the chief executive officer now owns 119,359 shares in the company, valued at $5,110,952.38. This trade represents a 5.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 133,679 shares of company stock worth $6,007,081. 22.87% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Jones Financial Companies Lllp increased its position in shares of Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock valued at $30,000 after buying an additional 357 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Mirum Pharmaceuticals in the 4th quarter valued at $35,000. GF Fund Management CO. LTD. purchased a new stake in Mirum Pharmaceuticals in the 4th quarter worth $42,000. R Squared Ltd acquired a new position in Mirum Pharmaceuticals during the fourth quarter worth $69,000. Finally, AlphaQuest LLC lifted its holdings in Mirum Pharmaceuticals by 969.6% during the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company’s stock valued at $76,000 after purchasing an additional 1,658 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.